Alizé Pharma has two entities under its wing. The first, Alizé Pharma SAS, is dedicated to a peptide (AZP-531) derived from its UAG (UnAcylated Ghrelin) analog, which is currently at the preclinical stage of development for the treatment of the Prader Willi Syndrome and Type II diabetes. The second, Alizé Pharma II SAS, is focused on the development of ASPAREC, a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, partnered with EUSA Pharma and currently in Phase I clinical development.

The funds raised will allow the company to launch clinical development of its UAG analog. It will carry out the first (Phase I) clinical trial of AZP-531 in healthy volunteers in 2013, which will be followed by Phase Ib and Phase II trials in patients with type II diabetes as well as in patients suffering from the Prader Willi syndrome. Preclinical and clinical data suggest that UAG and its analogs have therapeutic potential in the targeted indications, by reducing acylated ghrelin blood levels, improving glycemic control and insulin sensitivity, and improving additional cardiovascular risk factors.

Alizé Pharma has raised a total of €8.3 million since its creation in 2007.